TY - JOUR
AU - Yoon, Charles H
AU - Ross, Merrick I
AU - Gastman, Brian R
AU - Luke, Jason J
AU - Ascierto, Paolo A
AU - Long, Georgina V
AU - Rutkowski, Piotr
AU - Khattak, Muhammad
AU - Del Vecchio, Michele
AU - de la Cruz Merino, Luis
AU - Mackiewicz, Jacek
AU - Chiarion-Sileni, Vanna
AU - Schadendorf, Dirk
AU - Carlino, Matteo S
AU - Zhao, Yujie
AU - Fukunaga-Kalabis, Mizuho
AU - Krepler, Clemens
AU - Eggermont, Alexander M M
AU - Gershenwald, Jeffrey E
AU - Sondak, Vernon K
TI - Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.
JO - Annals of surgical oncology
VL - 32
IS - 4
SN - 1068-9265
CY - Berlin [u.a.]
PB - Springer
M1 - DKFZ-2025-00268
SP - 2756-2764
PY - 2025
N1 - 2025 Apr;32(4):2756-2764
AB - Previous results from the KEYNOTE-716 trial demonstrated significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) with adjuvant pembrolizumab versus placebo in patients with resected stage IIB or IIC melanoma. We present a post hoc analysis of efficacy according to primary tumor location.KEYNOTE-716 (NCT03553836) is a randomized, multicenter, double-blind, phase III study. Patients aged ≥ 12 years with newly diagnosed, resected stage IIB or IIC melanoma (sentinel node-negative) were randomly assigned (1:1) to pembrolizumab 200 mg every 3 weeks (2 mg/kg up to 200 mg for pediatric patients) or placebo. This post hoc analysis evaluated RFS and DMFS by primary tumor location of the head/neck, trunk, or extremities.Overall, 976 patients were assigned to pembrolizumab (n = 487) or placebo (n = 489). Median follow-up was 39.4 months (range 26.0-51.4). The hazard ratios HRs (95
KW - Adjuvant (Other)
KW - Adjuvant therapy (Other)
KW - Immune checkpoint inhibitors (Other)
KW - Melanoma (Other)
KW - Pembrolizumab (Other)
KW - Skin neoplasms (Other)
KW - Surgery (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:39893343
DO - DOI:10.1245/s10434-024-16642-6
UR - https://inrepo02.dkfz.de/record/298412
ER -